- Home
- CORT vs RARE Comparison
CORT vs RARE Comparison
Compare CORT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CORT
- RARE
- Stock Information
- Founded
- CORT 1998
- RARE 2010
- Country
- CORT United States
- RARE United States
- Employees
- CORT N/A
- RARE N/A
- Industry
- CORT Biotechnology: Pharmaceutical Preparations
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- CORT Health Care
- RARE Health Care
- Exchange
- CORT Nasdaq
- RARE Nasdaq
- Market Cap
- CORT 5.9B
- RARE 5.2B
- IPO Year
- CORT N/A
- RARE 2014
- Fundamental
- Price
- CORT $53.63
- RARE $43.82
- Analyst Decision
- CORT Strong Buy
- RARE Strong Buy
- Analyst Count
- CORT 4
- RARE 14
- Target Price
- CORT $75.25
- RARE $88.43
- AVG Volume (30 Days)
- CORT 824.2K
- RARE 721.5K
- Earning Date
- CORT 02-13-2025
- RARE 02-13-2025
- Dividend Yield
- CORT N/A
- RARE N/A
- EPS Growth
- CORT 57.97
- RARE N/A
- EPS
- CORT 1.26
- RARE N/A
- Revenue
- CORT $628,555,000.00
- RARE $522,745,000.00
- Revenue This Year
- CORT $46.29
- RARE $27.36
- Revenue Next Year
- CORT $17.09
- RARE $18.61
- P/E Ratio
- CORT $42.54
- RARE N/A
- Revenue Growth
- CORT 39.67
- RARE 27.44
- 52 Week Low
- CORT $20.84
- RARE $37.02
- 52 Week High
- CORT $62.22
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- CORT 46.46
- RARE 35.31
- Support Level
- CORT $49.51
- RARE $41.45
- Resistance Level
- CORT $60.90
- RARE $44.21
- Average True Range (ATR)
- CORT 2.69
- RARE 1.71
- MACD
- CORT -0.85
- RARE -0.17
- Stochastic Oscillator
- CORT 34.74
- RARE 27.72
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.